Study of mechanisms and clinical transformation of treatment of tendon injury with exosomes from adipose-derived stem cells silenced with TGIF1 gene

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039159

Enrollment

Unknown

Registered

2020-10-21

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tendon injury

Interventions

experimental group:Adipose stem cell derived exosomes reinfusion therapy with tgif1 gene silencing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age: 18-70 years old; 2. Patients with tendon-bone insertion tear or tendon repair confirmed by MRI / CT / ultrasound; 3. Patients with tendon-bone insertion tear and inflammation, mainly including rotator cuff injury, cruciate ligament tear, heel tendinitis, collateral ligament injury, tennis elbow, and other diseases; 4. Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients have received other research drugs in the last 30 days; 2. Taking traditional Chinese medicine at the same time; 3. Patients had viral active infection and the research leader believed that it would reduce the patient's tolerance; 4. Pregnancy or lactation; 5. Severe complications; 6. Severe heart disease, such as the history of congestive heart failure, arrhythmia, angina pectoris, etc.

Design outcomes

Primary

Measure	Time frame
MRI;Blood biochemical examination;Ultrasonography;Blood immunoassay;	—

Countries

China

Contacts

Public ContactCheng Biao

Shanghai Tenth People's Hospital

sybiaoc@163.com+86 13681973702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026